In sharp contrast with the lack of differences in most biomarkers among different AKI stages, when patients were classified into 4 categories according to the presence and type of AKI there were statistically significant differences in all biomarkers among the four groups, except for clusterin (Table 5). This evidence concerns the gene CLU and acute kidney injury.